- Solid company - Has had downward trend for weeks but is now at support - For the six months ended 30 June 2021, Amgen, Inc. revenues increased less than 1% to 12.43B. - Net income decreased 42% to 2.11B. Revenues reflect Prolia segment increase of 20% to 1.57B - Other revenues segment increase of 28% to 721M, also reflect Enbrel segment decrease of14% to 2.07B, Neulasta segment decrease of 19% to 968M. - Net income was partially offset by Research and development increase of 7% to 2.05B (expense), Selling.
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.